Breaking Down Chongqing Pharscin Pharmaceutical Co., Ltd. Financial Health: Key Insights for Investors

Chongqing Pharscin Pharmaceutical Co., Ltd. presents a compelling financial snapshot: quarterly revenue of CNY 202.97 million (quarter ended June 30, 2025), TTM revenue of CNY 798.88 million and 2024 annual revenue of CNY 774.82 million-a 12.04% rise from 2023 that outpaced the Pharmaceuticals industry growth of 5.8%; profitability shows a nine‑month net income of CNY 72.46 million (Sept. 30, 2025) with a net margin near 11.6%, gross margin ≈57.6% and operating cash flow of CNY 161.8 million, while balance‑sheet strength is underscored by cash and equivalents of CNY 456.6 million and minimal total debt of CNY 0.13 million yielding a net‑cash position; valuation metrics include a market cap of CNY 6.79 billion (Oct. 14, 2025) and a P/E of 86.90 with enterprise value CNY 5.76 billion (Dec. 18, 2025), set against risks such as a historical earnings decline averaging -16.9% and revenue erosion trends, and growth levers like R&D capabilities, nationwide sales coverage across 31 provinces, distribution to over 4,000 public hospitals and delivery to more than 8 million patients annually.

Chongqing Pharscin Pharmaceutical Co., Ltd. (002907.SZ) - Revenue Analysis

• Quarter ending June 30, 2025: revenue of CNY 202.97 million, +7.13% from prior quarter.
• Trailing twelve months (TTM) as of June 30, 2025: CNY 798.88 million, +6.67% year-over-year.
• Full year 2024 revenue: CNY 774.82 million, +12.04% vs. 2023, reversing a -11.93% decline in 2023 vs. 2022.
• 2024 revenue growth outperformed Pharmaceuticals industry average of 5.8%.
• Employees (latest report): 1,384; revenue per employee: not available.

• Revenue trajectory: decline in 2023 (-11.93%) followed by a recovery in 2024 (+12.04%) and continued sequential improvement into Q2 2025 (+7.13% q/q).
• TTM growth of 6.67% indicates stabilization and modest YoY momentum versus industry average.
• Key monitoring items for investors: sustainability of quarterly growth, drivers behind 2024 recovery (product mix, pricing, new launches, or channel improvements), and margin/earnings translation of top-line gains.

Chongqing Pharscin Pharmaceutical Co., Ltd. (002907.SZ) - Profitability Metrics

• Net income (9M 2025): CNY 72.46 million vs CNY 74.58 million (9M 2024).
• EPS (9M 2025): CNY 0.1735 vs CNY 0.1786 (9M 2024).
• Net profit margin (9M 2025): ~11.6%.
• Return on equity (ROE, 9M 2025): 4.8%.
• Gross profit margin (9M 2025): ~57.6%.
• Operating cash flow (9M 2025): CNY 161.8 million, substantially higher than net income (CNY 72.46 million), indicating strong cash conversion.

Chongqing Pharscin Pharmaceutical Co., Ltd. (002907.SZ) - Debt vs. Equity Structure

• Total debt: ~CNY 0.13 million (latest report)
• Net cash position: positive (debt is negligible relative to cash and liquid assets)
• Market capitalization: CNY 6.79 billion (as of 14 Oct 2025)
• Price-to-earnings (P/E) ratio: 86.90 (as of 14 Oct 2025)
• Enterprise value (EV): CNY 5.76 billion (as of 18 Dec 2025)
• Capital expenditures (CapEx): CNY 16.2 million (latest annual figure)

• Financial flexibility: Strong - net cash enables opportunistic investments or share-holder returns without relying on external debt markets.
• Leverage risk: Minimal - negligible interest burden and low default risk from financial obligations.
• Growth funding: Likely to come from operating cash flow or equity issuance if needed, given conservative reinvestment level.

Chongqing Pharscin Pharmaceutical Co., Ltd. (002907.SZ) - Liquidity and Solvency

• Operating cash flow (9M 2025): CNY 161.8 million - indicates robust cash generation from core operations.
• Cash and cash equivalents: CNY 456.6 million - substantial liquid buffer for day-to-day and contingency needs.
• Total debt: ~CNY 0.13 million - essentially negligible, reflecting a near-net-cash balance sheet.
• Net cash position: Strong - cash substantially exceeds debt, implying favorable liquidity despite current- and quick-ratio values not being explicitly disclosed.
• Revenue and profitability trends: Consistent growth and positive margins further reinforce solvency and debt-servicing capacity.

• Implications for investors: Low leverage plus strong cash generation lowers downside risk and improves the company's ability to pursue growth without relying on external financing.
• Areas to monitor: Changes in working capital dynamics, capex requirements, and any future debt issuance that could alter the currently favorable net-cash stance.

Chongqing Pharscin Pharmaceutical Co., Ltd. (002907.SZ) - Valuation Analysis

• Market capitalization: CNY 6.79 billion (as of October 14, 2025)
• P/E ratio: 86.90 (reflecting high market expectations for future earnings)
• Enterprise value (EV): CNY 5.76 billion (as of December 18, 2025)
• Share price resilience: trading at CNY 15.51 (as of December 12, 2025)

• The elevated P/E ratio (86.90) signals that investors expect substantial future earnings growth or premium margins relative to current earnings.
• EV (CNY 5.76 billion) below market cap suggests low net debt or positive cash balance, implying a relatively conservative capital structure.
• Valuation metrics align with industry norms for Chinese pharmaceutical firms that command premium multiples due to R&D pipelines and recurring product demand.
• Stock price at CNY 15.51 as of December 12, 2025 demonstrates market confidence and price stability despite the high P/E multiple.

Chongqing Pharscin Pharmaceutical Co., Ltd. (002907.SZ) - Risk Factors

• Earnings contraction: earnings have declined at an average annual rate of -16.9%, materially underperforming the Pharmaceuticals industry average growth of +5.8% per year.
• Top-line pressure: revenue has fallen at an average rate of -3.5% per year, signaling demand or execution challenges.
• Profitability under stress: net margin stands at 10.4%, while return on equity (ROE) is modest at 4.8%, limiting capital efficiency compared with peers.
• Market performance: market capitalization has decreased by 5.06% over the past 12 months, reflecting investor concerns and stock weakness.
• Share-price volatility: the stock has a 52-week trading range of CNY 11.42 to CNY 22.69, indicating elevated price swings and potential liquidity/volatility risk for traders and investors.
• Debt profile: debt levels are minimal, which reduces solvency risk but may also signal conservative growth financing or limited leverage to amplify returns.

• Operational risk: persistent earnings declines suggest issues with product mix, pricing, competitive positioning, or cost control.
• Execution risk: shrinking revenue undermines scale advantages; recovery will likely require successful new product launches or market share gains.
• Valuation/market risk: falling market cap and a wide 52-week range create downside risk for momentum-driven investors and complicate timing for entry/exit.
• Return risk: low ROE implies limited shareholder value generation unless profitability improves or capital allocation changes.
• Strategic risk: minimal debt reduces bankruptcy risk but may constrain accelerated expansion or M&A aimed at reversing declines.
• Liquidity & investor base risk: volatility may deter long-term institutional holders, increasing susceptibility to short-term flows.

Chongqing Pharscin Pharmaceutical Co., Ltd. (002907.SZ) - Growth Opportunities

• R&D and commercialization focus: sustained investment in translational R&D and regulatory affairs expertise tailored to Chinese approval pathways.
• Nationwide sales infrastructure: a professional marketing and sales team covering all 31 provinces and autonomous regions in China, enabling rapid product rollout and localized market execution.
• Hospital penetration and patient reach: products available in more than 4,000 public hospitals and delivered to over 8 million patients annually, indicating strong clinical adoption and recurring revenue potential.
• Industry experience: over 20 years operating within China's pharmaceutical landscape, yielding durable institutional knowledge and stakeholder relationships.
• Regulatory navigation advantage: accumulated experience handling complex interactions with government bodies and responding to policy shifts, reducing commercialization friction and time-to-market risk.